Uremia and cancer;Le point sur.., urémic et cancer

Nephrologie

Volumn 23, Issue 6, 2002, Pages 231-236

  Viron, B ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Cancer; Carcinogens; Dialysis; Immune status; Uremia

Indexed keywords

ANALGESIC AGENT; CARCINOGEN; IMMUNOSUPPRESSIVE AGENT; IRON; NUCLEIC ACID; SELENIUM;

ANALGESIC AGENT ABUSE; BIOCOMPATIBILITY; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHINESE HERB; DISEASE ASSOCIATION; ECHOGRAPHY; GEOGRAPHIC DISTRIBUTION; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNE RESPONSE; IRON DEFICIENCY; KIDNEY CARCINOMA; OXIDATIVE STRESS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SELENIUM DEFICIENCY; SOLID TUMOR; UREMIA;

HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; SUBSTANCE-RELATED DISORDERS; UREMIA;

EID: 0036379683     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Increased incidence of malignancy during chronic renal failure
2. Increased incidence of malignancy in chronic renal failure
3. Cancer in patients on hemodialysis
4. Neoplasia in patients with chronic renal failure on long-term dialysis
5. High incidence of neoplasia in uremic patients receiving long-term dialysis
6. Neoplasms in dialysis patients: A population-based study
7. Development of malignancy in the end-stage renal disease patient
8. Evidence for increased cancer deaths in chronic dialysis patients
9. Cancer among patients on renal remplacement therapy: A population-based survey in Lombardy, Italy
10. Cancer risk in patients on dialysis and after renal transplantation
11. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study
12. Renal neoplasias in patients receiving dialysis and renal transplantation: Clinicopathological features and P53 gene mutations
13. Incidence and spectrum of dialysis-associated cancer in three continents
14. Urologic cancers in uremic patients
15. Malignant tumors in hemodialysis patients
16. Renal pelvic neoplasms and atypical urothelium in patients with end-stage analgesic nephropathy
17. Urothelial lesions in Chinese-herb nephropathy
18. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)
19. Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (MutaMouse)
20. Cydophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis
21. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis
22. Balkan endemic nephropathy and associated urinary tract tumours: A review on aetiological causes and the potential role of mycotoxins
23. Elevation of levels of carcinogenic tryptophan pyrolysis products in plasma and red blood cells of patients with uremia
24. Significant increase of IQ-type heterocyclic amines, dietary carcinogens in the plasma of patients with uremia just before induction of hemodialysis treatment
25. N-nitrosodimethylamine blood levels in patients with chronic renal failure: Modulation of levels by ethanol and ascorbic acid
26. The renal risks of smoking
27. Cancer in end-stage renal disease: Potential factors involved
28. Elevated nicotine levels in patients undergoing hemodialysis. A role in cardiovascular mortality and morbidity?
29. End-stage renal disease serum contains a specific renal cell growth factor
30. DNA repair and recovery of RNA synthesis in uremic patients
31. The immune status of the uremic patient: Hemodialysis versus CAPD
32. Depressed natural killer cell activity in uremia. Evidence for immunosuppressive factor in uremic sera
33. Secondary hyperparathyroidism and the immune system in chronic renal failure
34. Is there an association between neoplasm and primary or secondary hyperparathyroidism?
35. Selenium depletion in hemodialysis patients treated with polysulfone membranes
36. Selenium and hemodialysis: Serum selenium levels in healthy persons, noncancer and cancer-patients with chronic renal failure
37. Enhancement of mammary carcinogenesis by a high-fat diet in Fischer, Long-Evans, and Sprague-Dawley rats
38. Humoral inhibitors of the immune response in uremia. IV Effects of serum and of isolated serum very low density lipoprotein from uremic rats on cellular immune reactions in vitro
39. Membrane protein damage and methylation reactions in chronic renal failure
40. A cancer risk assessment of di(2-ethylhexyl)phtalate: Application of the US EPA risk assessment guidelines
41. Increased risk of malignancy and blood-membrane interactions in uraemic patients
42. Recommendations on cancer screening in the European union. Advisory Committee on Cancer Prevention
43. Cost-effectiveness of cancer screening in end-stage renal disease
44. A reconsideration of the benefits of cancer screening in dialysis patients
45. Impact of chronic dialysis on serum PSA, free PSA and free/total PSA ratio: Is prostate cancer detection compromised in patients receiving long-term dialysis?
46. Elevated serum CA-125 levels in dialysis patients with peritoneal, pleural or pericardial fluids
47. Tumor markers in patients undergoing hemodialysis or kidney transplantation
48. Screening for acquired cystic kidney disease: A decision analytic perspective